ArticleAmerican journal of translational research2025
Post-procedural anticoagulation enhances cognitive function and reduces stroke risk in atrial fibrillation patients after left atrial appendage occlusion.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of post-left atrial appendage (LAA) occlusion anticoagulation strategy adjustments on cognitive function in atrial fibrillation (AF) patients, showing the influence of these adjustments on long-term brain health.
methodsIn this retrospective cohort study, a total of 210 patients with AF subjected to left atrial appendage (LAA) closure between January 2022 and January 2025 were included. Among them, 103 patients received anticoagulation treatment following the procedure (observation group) and 107 did not (control group). The primary outcome - cognitive function - was evaluated using the Mini-Mental State Examination (MMSE) scale and other cognitive tests. The secondary outcomes, including major adverse events (stroke [ischemic, hemorrhagic], transient ischemic attack, major bleeding, and venous thrombotic event), blood biochemical values (fasting blood glucose [FBG], low-density lipoprotein [LDL], high-density lipoprotein (HDL), triglycerides (TG), prothrombin time [PT], activated partial thromboplastin time [aPTT], fibrinogen, and D-Dimer), and quality-of-life scores (Physical, Mental Health, and Social Functioning) were also recorded and compared between groups.
resultsPost-procedure anticoagulation therapy significantly improved both cognitive function and clinical outcomes in AF patients undergoing LAA occlusion. The observation group demonstrated significantly better performances in the MMSE, attention, working memory, and visual-spatial abilities (all P<0.001). The FBG and LDL levels (both P<0.001) were significantly lower in the observation group compared to the control group, as was the incidence of ischemic stroke (1.9 vs. 5.6%) (P = 0.032). Quality of life scores, including physical, mental, and social functioning, were all significantly better in the observation group (P<0.001). Anticoagulation effects were evident, with significantly prolonged PT and aPTT in the observation group (P<0.001). Logistic regression analysis identified anticoagulation therapy as a significant predictor of reduced cognitive impairment (OR = 0.940, 95% CI: 0.910-0.972, P<0.001), indicating its potential benefit in preserving cognitive function after LAA occlusion.
conclusionPost-procedural anticoagulation therapy significantly improves cognitive function, reduces ischemic stroke incidence, and enhances quality of life in AF patients following LAA occlusion, highlighting its clinical value in management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.